Reproductive BioMedicine Online
Volume 20, Issue 3 , Pages 350-357 , March 2010

Outcomes after early or midfollicular phase LH supplementation in previous inadequate responders

  • M. Sönmezer

      Affiliations

    • IVF Unit, Department of Obstetrics and Gynecology, School of Medicine, Ankara University, Ankara, Turkey
    • Center for Research on Human Reproduction (USAUM), Ankara University, Ankara, Turkey
    • Corresponding Author InformationCorresponding author.
    • ,
  • C. İltemir Duvan

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Fatih University, Istanbul, Turkey
    • ,
  • B. Özmen

      Affiliations

    • IVF Unit, Department of Obstetrics and Gynecology, School of Medicine, Ankara University, Ankara, Turkey
    • Center for Research on Human Reproduction (USAUM), Ankara University, Ankara, Turkey
    • ,
  • T. Taşçı

      Affiliations

    • IVF Unit, Department of Obstetrics and Gynecology, School of Medicine, Ankara University, Ankara, Turkey
    • ,
  • S. Özkavukçu

      Affiliations

    • IVF Unit, Department of Obstetrics and Gynecology, School of Medicine, Ankara University, Ankara, Turkey
    • Center for Research on Human Reproduction (USAUM), Ankara University, Ankara, Turkey
    • ,
  • C.S. Atabekoğlu

      Affiliations

    • IVF Unit, Department of Obstetrics and Gynecology, School of Medicine, Ankara University, Ankara, Turkey
    • Center for Research on Human Reproduction (USAUM), Ankara University, Ankara, Turkey

Received 26 February 2009 ,Revised 18 March 2009 ,Accepted 16 November 2009.

References 

  1. Asian Puregon Study GroupHoomans EHM, Mulder BB. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon®) in Asian women undergoing ovarian stimulation for IVF/ICSI. J. Assist. Reprod. Genet. 2002;19:470–476
  2. Balasch J, Vidal E, Peñarrubia J, et al. Suppression of LH during ovarian stimulation, analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum. Reprod. 2001;16:1636–1643
  3. Barrenetxea G, Agirregoikoa JA, Jiménez MR, et al. Ovarian response and pregnancy outcome in poor-responder women, a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil. Steril. 2008;89:546–553
  4. Costagliola S, Niccoli P, Florentino M, et al. European collaborative study on luteinizing hormone assay, 2. Discrepancy among assay kits is related to variation both in standard curve calibration and epitope specificity of kit monoclonal antibodies. J. Endocrinol. Invest. 1994;17:407–416
  5. De Placido G, Alviggi C, Mollo A, et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin. Endocrinol. (Oxf.). 2004;60:637–643
  6. De Placido G, Alviggi C, Perino A, et al. Italian Collaborative Group on Recombinant Human Luteinizing Hormone. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum. Reprod. 2005;20:390–396
  7. De Placido G, Mollo A, Alviggi C, et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum. Reprod. 2001;16:1875–1879
  8. Esposito MA, Barnhart KT, Coutifaris C, et al. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil. Steril. 2001;75:519–524
  9. Ferrari B, Barusi L, Coppola F. Clinical and endocrine effects of ovulation induction with FSH and hCG supplementation in low responders in the midfollicular phase. A pilot study. J. Reprod. Med. 2002;47:137–143
  10. Fevold HL. Synergism of follicle stimulating and luteinizing hormones in producing estrogen secretion. Endocrinology. 1941;28:33–36
  11. Filicori M, Cognigni GE, Taraborrelli S, et al. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J. Clin. Endocrinol. Metab. 1999;84:2659–2663
  12. Fleming R, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum. Reprod. 1998;13:1788–1792
  13. Greep RO, Van Dyke HB, Chow BF. Gonadotropin of swine pituitary, various biological effects of FSH and ICSI. Endocrinology. 1942;30:635–649
  14. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Human Reproduction. 1994;9:188–191
  15. Huhtaniemi I, Jiang M, Nilsson C, et al. Mutations and polymorphisms in gonadotropin genes. Mol. Cell. Endocrinol. 1999;151:89–94
  16. Humaidan P. To add or not to add LH, comments on a recent commentary. Reprod. Biomed. Online. 2006;12:284–285
  17. Humaidan P, Bungum L, Bungum M, et al. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum. Reprod. 2002;17:2016–2021
  18. Humaidan P, Bungum M, Bungum L, et al. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH, an opening study. Reprod. Biomed. Online. 2004;8:635–643
  19. Jiang M, Pakarinen P, Zhang FP, et al. A common polymorphic allele of the human luteinizing hormone beta-subunit gene, additional mutations and differential function of the promoter sequence. Hum. Mol. Genet. 1999;8:2037–2046
  20. Laml T, Obruca A, Fischl F, et al. Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women. Gynecol. Endocrinol. 1999;13:98–103
  21. Lisi F, Rinaldi L, Fishel S, et al. Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF, a preliminary study. Reprod. Biomed. Online. 2001;3:190–194
  22. Marrs R, Meldrum D, Muasher S, et al. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod. Biomed. Online. 2004;8:175–182
  23. McNatty KP, Hunter WM, MacNeilly AS, et al. Changes in the concentration of pituitary and steroid hormones in the follicular fluid of human graafian follicles throughout the menstrual cycle. J. Endocrinol. 1975;64:555–571
  24. Niccoli P, Costagliola S, Patricot MC, et al. European collaborative study of LH assay, 3. relationship of immunological reactivity, biological activity and charge of human luteinizing hormone. J. Endocrinol. Invest. 1996;19:260–267
  25. Nyboeandersen A, Humaidan P, Fried G, et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum. Reprod. 2008;23:427–434
  26. Oliveira JB, Mauri AL, Petersen CG, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulation hormone during induced ovarian stimulation in the GnRHagonist protocol, a meta-analysis. J. Assist. Reprod. Genet. 2007;24:67–75
  27. Out JH, David I, Ron-El R, et al. A randomized, double-blind clinical trial using fixed dialy doses of 100 or 200IU of recombinant FSH in ICSI cyles. Hum. Reprod. 2001;16:1104–1109
  28. Out JH, Lindenberg S, Mikkelsen AN, et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing ovarian stimulation. Hum. Reprod. 1999;14:622–627
  29. Peñarrubia J, Fábregues F, Creus M, et al. LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. Hum. Reprod. 2003;18:2689–2697
  30. Ropelato MG, Garcia-Rudaz MC, Castro-Fernandez C, et al. A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 1999;84:4629–4636
  31. Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil. Steril. 2002;77:1170–1177
  32. The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women, a dose-finding study. J. Clin. Endocrinol. Metab. 1998;83:1507–1514
  33. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum. Reprod. 2000;15:1003–1008

 Dr Sonmezer has been working on reproductive medicine at Ankara University, School of Medicine, Department of Obstetrics and Gynaecology, and Center for Research on Human Reproduction. He completed a research doctorate program on assisted reproduction at the University of Cornell-USA under the supervision of Professor Dr Kutluk Oktay. He is interested in human oocyte and ovarian tissue cryopreservation, sperm DNA damage and ovulation induction in poor responders.

PII: S1472-6483(09)00275-2

doi: 10.1016/j.rbmo.2009.11.022

Reproductive BioMedicine Online
Volume 20, Issue 3 , Pages 350-357 , March 2010

Article Tools

* Image Usage & Resolution